Skip to main content

Table 2 Multivariate analyses of outcomes

From: Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients

Outcome

Hazard ratio (95% CI)

P value

ANC recovery

 Cohort ATG-PTCy vs ATG

0.29 (0.21–0.41)

< 0.001

Other significant factors

 Mononuclear cell count

1.09 (1.04–1.14)

< 0.001

 CD34+ cell count

1.08 (1.01–1.15)

0.012

Platelet recovery

 Cohort ATG-PTCy vs ATG

0.30 (0.21–0.42)

< 0.001

Other significant factors

 Mononuclear cell count

1.06 (1.01–1.11)

0.008

Acute GvHD ≥ grade 2

 Cohort ATG-PTCy vs ATG

0.58 (0.35–0.96)

0.036

Acute GvHD ≥ grade 3

 Cohort ATG-PTCy vs ATG

0.28 (0.11–0.69)

0.006

Total chronic GvHD

 Cohort ATG-PTCy vs ATG

0.60 (0.38–0.99)

0.047

Non-relapse mortality

 Cohort ATG-PTCy vs ATG

0.26 (0.08–0.75)

0.014

Disease risk index

 Low/int vs high

0.28 (0.12–0.68)

0.005

Relapse

 Cohort ATG-PTCy vs ATG

0.65 (0.28–1.50)

0.31

Disease-free survival

 Cohort ATG-PTCy vs ATG

0.44 (0.22–0.86)

0.016

Disease risk index

 Low/int vs high

0.51 (0.27–0.99)

0.048

Overall survival

 Cohort ATG-PTCy vs ATG

0.47 (0.22–1.01)

0.055

Disease risk index

 Low/int vs high

0.48 (0.23–0.99)

0.048

GVHD and relapse-free survival

 Cohort ATG-PTCy vs ATG

0.59 (0.38–0.92)

0.021